-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
More than 50 million people worldwide suffer from dementia
"There are different biomarkers in the rapid development of Alzheimer's disease in recent years, allowing us to measure and detect the early signs of the disease in patients," said Marco Bucci, the first author of the study, of the Alzheimer's Research Center.
Some biomarkers can identify A? or tau protein, while others are used to measure the loss of nerve function (neurodegeneration)
Dr.
This result is based on brain imaging (PET and MRI) and cerebrospinal fluid analysis of 282 participants, including patients with mild cognitive impairment, patients with Alzheimer's disease, and healthy controls
"Our research results show that the concentration of tau protein in the brain of Alzheimer's disease plays an important role in its pathological progress, and may become a key target for future drug therapy," Karolinska Institute Alzheimer's Said Professor Agneta Nordberg, the principal investigator of the Center for Disease Research
This research was funded by the Swedish Strategic Research Foundation, the Swedish Research Council, the Stockholm Region, the Swedish Brain Foundation, the Swedish Alzheimer's Disease Foundation, the Center for Innovative Medicine, and the Swedish Medical Research Association
Journal Reference :
Marco Bucci, Konstantinos Chiotis, Agneta Nordberg.